Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors
05. August 2024 08:00 ET
|
Avalyn Pharma Inc.
CAMBRIDGE, Mass., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for life-threatening pulmonary...
Avalyn to Participate in Multiple Upcoming Investor Conferences
01. August 2024 08:00 ET
|
Avalyn Pharma Inc.
CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for life-threatening pulmonary...
Avalyn to Participate in Jefferies Global Healthcare Conference
28. Mai 2024 08:00 ET
|
Avalyn Pharma Inc.
CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for life-threatening pulmonary diseases,...
Avalyn Presents Clinical Data on AP01 for Pulmonary Fibrosis, Including Long-Term Efficacy and Imaging Biomarker Data, at ATS 2024
20. Mai 2024 16:16 ET
|
Avalyn Pharma Inc.
AP01 (Inhaled Pirfenidone) Treatment Demonstrated Substantially Improved Efficacy and Tolerability Out to 3.5 Years Compared to Historical Data with Oral Pirfenidone Additional Poster Presentations...
Avalyn Announces Multiple Presentations on its Lead Program, AP01, for Pulmonary Fibrosis and its Approach to Developing Novel Inhaled Therapies for Lung Diseases at the 2024 American Thoracic Society International Conference
13. Mai 2024 08:00 ET
|
Avalyn Pharma Inc.
Presentations to Include Long-term Safety and Efficacy Data from the ATLAS Trial Extension Study of AP01 (Inhaled Pirfenidone) for Pulmonary Fibrosis Avalyn to be featured in ATS Mini Theater Program...
Avalyn Bolsters Leadership Team with the Appointment of Douglas Carlson as Chief Financial Officer and Chief Business Officer
01. Mai 2024 08:00 ET
|
Avalyn Pharma Inc.
CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhaled therapies for life-threatening pulmonary diseases,...
Avalyn to Participate in Leerink Partners Global Biopharma Conference
06. März 2024 08:00 ET
|
Avalyn Pharma Inc.
CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhalation therapies for life-threatening pulmonary...
Avalyn to Participate in Multiple Upcoming Investor Conferences
06. Februar 2024 08:00 ET
|
Avalyn Pharma Inc.
CAMBRIDGE, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of inhalation therapies for life-threatening pulmonary...
Avalyn to Participate in the 2023 RBC Capital Markets Healthcare Private Company Conference
06. Dezember 2023 08:00 ET
|
Avalyn Pharma Inc.
SEATTLE, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation therapies for life-threatening pulmonary...
Avalyn Presents Data from its AP01 and AP02 Inhaled Therapeutics Programs for Pulmonary Fibrosis
09. November 2023 08:00 ET
|
Avalyn Pharma Inc.
Preclinical data that supported initiation of the completed Phase 1a AP02 inhaled nintedanib study to be presented for the first time at the PFF Summit AP01 inhaled pirfenidone clinical data,...